1-(5-chloropyridin-2-yl)piperidine-4-carboxylic acid | 953751-20-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(5-chloropyridin-2-yl)piperidine-4-carboxylic acid
• 英文别名: 5'-Chloro-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-carboxylic acid
• CAS: 953751-20-7
• 化学式: C₁₁H₁₃ClN₂O₂
• mdl: MFCD09733806
• 分子量: 240.689
• InChiKey: YOSRZAOSDZTMAM-UHFFFAOYSA-N

物化性质

• 沸点：
  441.0±45.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  53.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(5-chloropyridin-2-yl)piperidine-4-carboxylic acid 、 2-[3-(aminomethyl)-2-fluoro-6-(trifluoromethyl)phenyl]-6-ethyl-5-fluoropyrimidin-4(3H)-one 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-(5-chloropyridin-2-yl)-N-[3-(4-ethyl-5-fluoro-6-oxo-1,6-dihydropyrimidin-2-yl)-2-fluoro-4-(trifluoromethyl)benzyl]piperidine-4-carboxamide
  参考文献：
  名称：

  [EN] PYRIMIDINE DERIVATIVES
  [FR] DÉRIVÉS DE PYRIMIDINE
  [JA] ピリミジン誘導体

  摘要：

  mPGES-1に対して強い阻害作用を有し炎症などの治療のための医薬の有効成分として有用な下記一般式(1)の化合物。

  公开号：

  WO2024010015A1

文献信息

• Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040220191A1

  公开（公告）日：2004-11-04

  The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I 1 in which the radicals have the stated meanings, the N-oxides and the physiologically tolerated salts thereof and process for the preparation thereof are described. The compounds are suitable for example as anorectic agents.

  这项发明涉及取代N-芳基杂环化合物及其生理耐受盐和生理功能衍生物。式I的化合物 1 其中基团具有所述含义，其N-氧化物及其生理耐受盐以及其制备方法被描述。这些化合物例如适用作为厌食剂。
• PYRROLIDINE DERIVATIVES
  申请人：Knust Henner

  公开号：US20110144081A1

  公开（公告）日：2011-06-16

  The present invention relates to compounds of formula wherein R 1 , R 2 , R 3 , R 4 , Z, and n are as defined herein or to a pharmaceutically active salt thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及以下式中的化合物，其中R1、R2、R3、R4、Z和n如本文所定义，或其药用活性盐。本发明的化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。
• [EN] PYRROLIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRROLIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011085886A1

  公开（公告）日：2011-07-21

  The present invention relates to compounds of formula (I) or to a pharmaceutically active salt thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及式(I)的化合物或其药用活性盐。已发现这些化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。
• [EN] PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS<br/>[FR] DERIVES CARBOXAMIDES DE PIPERIDINE/CYCLOHEXANE DESTINES A ETRE UTILISES COMME MODULATEURS DU RECEPTEUR VANILLOIDE
  申请人：GLAXO GROUP LTD

  公开号：WO2005016915A1

  公开（公告）日：2005-02-24

  Certain compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, P, P', X, m and n are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds in medicine, as vanilloid receptor modulators.

  某些式（I）化合物，或其药学上可接受的盐或溶剂合物，其中R1、R2、P、P'、X、m和n如说明书中所定义，制备此类化合物的方法，包含此类化合物的药物组合物，以及此类化合物在医学中作为香草素受体调节剂的用途。
• [EN] INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS<br/>[FR] INHIBITEURS D'ARGINASE ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：MARS INC

  公开号：WO2011133653A1

  公开（公告）日：2011-10-27

  Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity : Formule (I), (II) where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

  根据式I和式II，化合物是Arginase I和II活性的强效抑制剂：式(I)，(II)中的R1、R2、R3、R4、R5、R6、R7、R8、R9、D、M、X和Y的定义如规范所述。该发明还提供了这些化合物的药物组合物以及它们用于治疗或预防与Arginase活性相关的疾病或病况的方法。